Adaptive resistance to anti-PD1 therapy by tim-3 upregulation is mediated by the PI3k-akt pathway in head and neck cancer

OncoImmunology

Volumn 6, Issue 1, 2017, Pages

  Shayan, Gulidanna ^a   Srivastava, Raghvendra ^b   Li, Jing ^a   Schmitt, Nicole ^b   Kane, Lawrence P ^b   Ferris, Robert L ^b,c  

^a Tsinghua University   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Head and neck cancer; Immunotherapy; Monoclonal antibody; PD 1; Tim 3

Indexed keywords

GILVETMAB; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; NIVOLUMAB;

ADULT; AGED; ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PHOSPHORYLATION; PI3K/AKT SIGNALING; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

EID: 85009205136     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1261779     Document Type: Article

References (38)

1. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9; PMID:21739672; http://dx.doi.org/10.1038/ni.2035
2. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8C T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10:29-37; PMID:19043418; http://dx.doi.org/10.1038/ni.1679
3. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8C T cell exhaustion during chronic viral infection. Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/10.1016/j. immuni.2007.09.006
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi. org/10.1056/NEJMoa1200690
6. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015; 33:3293-304; PMID:26351330; http://dx.doi.org/10.1200/JCO.2015.61.1509
7. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014; 50:627-32; PMID:24819861; http://dx.doi.org/10.1016/j.oraloncology. 2014.04.003
8. Laban S, Doescher J, Schuler PJ, Bullinger L, Brunner C, Veit JA et al. Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015. Hno 2015; 63:612-9; PMID:26319429; http://dx.doi. org/10.1007/s00106-015-0054-1
9. Ferris RL, Blumenschein, Jr. G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856-1867; PMID:27718784; http://dx.doi.org/10.1056/NEJMoa1602252
10. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011; 32:345-9; PMID:21697013; http://dx.doi.org/10.1016/j.it.2011.05.003
11. Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Topics Microbiol Immunol 2011; 350:1-15; PMID:20700701; http://dx.doi.org/10.1007/82_2010_84
12. Gorman JV, Colgan JD. Regulation of T cell responses by the receptor molecule Tim-3. Immunologic Res 2014; 59:56-65; PMID:24825777; http://dx.doi.org/10.1007/s12026-014-8524-1
13. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-51; PMID:21430066; http://dx.doi.org/10.1158/0008-5472. CAN-11-0096
14. Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion 2014; 193:1525-30; PMID:25086175; http://dx.doi.org/10.4049/jimmunol.1400557
15. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8C T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637
16. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, Freeman GJ, Kuchroo VK, Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010; 107:14733-8; PMID:20679213; http://dx.doi.org/10.1073/pnas.1009731107
17. Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L et al. PD-1(hi)TIM-3(C) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J 2015; 5:e330; PMID:26230954; http://dx.doi.org/10.1038/bcj.2015.58
18. Li J, Shayan G, Avery L, Jie H-B, Gildener-Leapman N, Schmitt N, Lu B, Kane LP, Ferris RL. Tumor-infiltrating Tim-3C T cells proliferate avidly except when PD-1 is co-expressed: evidence for intracellular cross talk. Oncoimmunology. 2016 Sep 22;5(10):e1200778; PMID:27853635; http://dx.doi.org/10.1080/2162402X.2016.1200778
19. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
20. Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015; 75:508-18; PMID:25480946; http://dx.doi.org/10.1158/0008-5472.CAN-14-1215
21. Ferris RL, Lu B, Kane LP. Too Much of a Good Thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol 2014; 193:1525-30; PMID:25086175; http://dx.doi.org/10.4049/jimmunol.1400557
22. Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013; 109:2629-35; PMID:24169351; http://dx.doi.org/10.1038/bjc.2013.645
23. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 108:766-72; PMID:14696105; http://dx.doi.org/10.1002/ijc.11633
24. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-75; PMID:15734974; http://dx.doi.org/10.1158/1055-9965.EPI-04-0551
25. Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Archives Otolaryngol Head Neck Surg 2007; 133:495-502; PMID:17515506; http://dx.doi.org/10.1001/archotol.133.5.495
26. Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol 2015; 23:82-91; PMID:26093105; http://dx.doi.org/10.1016/j. coph.2015.05.017
27. Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta 2015; 1851:882-97; PMID:25514767; http://dx.doi.org/10.1016/j.bbalip.2014.12.006
28. Koyasu S. The role of PI3K in immune cells. Nat Immunol 2003; 4:313-9; PMID:12660731; http://dx.doi.org/10.1038/ni0403-313
29. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annual Rev Immunol 2013; 31:675-704; PMID:23330955; http://dx.doi.org/10.1146/annurev-immunol-032712-095946
30. Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer 2015; 3:54; PMID:26579227; http://dx.doi.org/10.1186/s40425-015-0097-6
31. Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM, Mkrtichyan M, Khleif SN. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res 2014; 2:1080-9; PMID:25080445; http://dx.doi.org/10.1158/2326-6066.CIR-14-0095
32. Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M, Fu_c_ıková J, Truxová I, Tachezy R, Špîśek R et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 2015; 4:e965570; PMID:25949860; http://dx.doi.org/10.4161/21624011.2014.965570
33. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472. CAN-12-2606
34. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016; 7:10501; PMID:26883990; http://dx.doi.org/10.1038/ncomms10501
35. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8C T cells. J Exp Med 2015; 212:1125-37; PMID: 26034050; http://dx.doi.org/10.1084/jem.20142237
36. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP 2. J Exp Med 2012; 209:1201-17; PMID:22641383; http://dx.doi.org/10.1084/jem.20112741
37. Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol 2013; 33:3091-8; PMID:23732914; http://dx.doi.org/10.1128/MCB.00319-13
38. Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, Sakhdari A, Benko E, Kovacs C, Ostrowski MA. Antigen-independent induction of Tim-3 expression on human T cells by the common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol 2012; 188:3745-56; PMID:22422881; http://dx.doi.org/10.4049/jimmunol.1102609